MedTrace Logo

Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery

NCT01096875 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-07-09

Study results available
· View outcomes & findings →

Summary

Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.

Conditions

  • Coronary Artery Bypass Surgery
  • Elective Surgical Procedure

Interventions

DRUG

Atorvastatin

40mg/day once daily for two weeks prior to surgery

DRUG

Placebo

1tb/day once daily for two weeks prior to surgery

Sponsors & Collaborators

  • Turkish Society of Hematology

    collaborator OTHER

  • Ankara University

    lead OTHER

Principal Investigators

  • RUCHAN AKAR, Assoc. Prof. · Ankara University Medical Faculty, Department of Cardiovascular Surgery Ankara, Turkey, 06340

  • ONDER ASLAN, Prof. · Ankara University Medical Faculty, Department of Hematology Ankara, Turkey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-07-31
Completion
2010-10-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01096875 on ClinicalTrials.gov